Unilife Corporation UNIS, a U.S. based designer, developer and
manufacturer of injectable drug delivery systems, today announced the signing
of a long-term supply contract with Sanofi.
Unilife has agreed to supply Sanofi with the Unifill Finesse^™, a customized
device from its Unifill^® platform of prefilled syringes with automatic,
needle retraction, for use with the anti-thrombotic therapy Enoxaparin Sodium
sold under the brand names Lovenox^® and Clexane^® ("Lovenox"). The contract
period can extend up to 2024.
Unilife has granted Sanofi the exclusive use of the Unifill Finesse with
anti-thrombotic drugs during the contract period. Following a four year
ramp-up period after market entry, exclusivity will be maintained, subject to
Sanofi purchasing a minimum of 150 million units of the Unifill Finesse or
other Unifill syringes per year.
Unilife can supply its Unifill syringes, including the Unifill Finesse, to
additional customers in all other therapeutic classes outside of
anti-thrombotics.
In addition to future revenue from the sale of Unifill Finesse syringes,
Unilife may receive up to $15 million from Sanofi in milestones based payments
with $5 million of these payments expected in 2013.
This supply contract replaces and supersedes all other agreements previously
signed between both parties regarding the Unifill syringe platform. For
commercial purposes and due to confidentiality clauses in the Agreement,
additional terms of the contract are to remain confidential.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in